2026. Cost–Benefit Evaluation of Interferon and Ribavirin for the Treatment of Hepatitis C in District Dera Ismail Khan, Pakistan. Physical Education, Health and Social Sciences. 4, 1 (Feb. 2026), 129–136. DOI:https://doi.org/10.63163/jpehss.v4i1.1040.